You'll Probably Be Back: What MDD and TRD Patients Should Really Expect from Psychedelic Therapy and How Care Providers Should Be Talking About It

There's a particular kind of hope that arrives with a first ketamine infusion, or a first psilocybin session. For many people living with Major Depressive Disorder (MDD) or Treatment-Resistant Depression (TRD), it's the first time in years, sometimes ever, that the weight has lifted.

But there's a conversation that doesn't always follow that moment — one that clinicians might not be having, that medical staff don't always know how to approach, and that marketing materials rarely want to touch. It's the conversation about what happens next. When asked directly, clinical staff will be transparent, for the most part. They’ll explain that the therapeutic journey is lifelong, and that psychedelic-assisted therapy is not a magic bullet, nor a promised cure.

What we don’t talk about enough, even amongst ourselves as scientists and clinicians, is the longer arc. Just as someone with TRD might take an oral antidepressant every day for the rest of their life, that same person might return yearly for a couple of booster ketamine sessions, a full 8-week protocol, or one or two additional psilocybin sessions. Year after year. After year, after year. And they will very likely remain in therapy throughout. That isn't failure. If anything, it's a more profound and meaningful process than a daily pill that manages symptoms without ever asking anything of the person taking it — that numbs and flattens, without ever encouraging them to hold up the mirror, dig deeper, get to know themselves better, or show up more fully to their own life.

And let's be honest about something else: different chapters of life have a way of bringing people back to the work they thought they'd already done. Every significant challenge — grief, transition, rupture, growth — is an invitation to look in the mirror again. For those with a history of MDD or TRD, that reality is even more pronounced. The mirror doesn't go away. But with the right tools and the right support, people get better at facing it.

So what does that actually look like? What happens in the months and years following a profound psilocybin therapy journey, or an 8-week ketamine protocol? What should we be saying to new patient callers? Or to the patient who does beautifully for eight months and then feels the darkness return?

This is the return visit nobody talks about.

But we should talk about it! For someone living with TRD, needing support again should be completely normal and expected. It was always part of the journey, and that expectation should be introduced early. Remission isn't a destination; not for MDD, and not for TRD. It's more accurately understood as a season, one that can be long and full and genuinely life-changing, but one that exists within a larger cycle. Ketamine and psilocybin therapy are extraordinary tools precisely because they can induce that remission with far less frequent administration than a daily antidepressant. But less often is not the same as never. Understanding that distinction is part of what it means to truly care for this population.

Which brings us to how we're framing the conversation in the first place.

When we talk about educating patients, the work isn't limited to explaining mechanisms or safety profiles. It's about helping people understand what their lives might actually look like on the other side. How these therapies can improve quality of life. How they help find meaning and purpose, deepen relationship to self and to others, shift perspective, catalyze growth, and meet life's most difficult chapters with more capacity than before. Not by feeling less, but by actually feeling more, knowing more, being more.

These therapies won't fix anyone. There is no fixing. But they will improve the human experience of those who engage with them earnestly. And if someone has struggled with TRD, be it for a year or for most of their life, their therapeutic journey is going to be a long one. That's not a caveat. It's simply the truth of it.

It's also everyone's truth, to varying degrees. All of our meaning-making journeys are lifelong — they just look different from person to person. For some, depth and support come through talk therapy or other therapeutic modalities. For others it's a practice, a life-coach or teacher, a sport, an art, a regular workshop, meditation, or a personally-guided ritual. And for others still, it will be psychedelic-assisted therapy within a clinical container — perhaps rotating through different modalities over time, all guided with intention.

The through-line isn't the method, it's really the commitment to the work. And that begins with how we communicate, educate, and set expectations that are realistic, held with care and encouragement, rather than false promise. We must also reckon with the broader cultural current we're swimming against: a societal mindset that chases cures, rewards quick fixes, and stigmatizes the person who still needs support. Lifelong self-work is courageous, clarifying, and, honestly, necessary. Whether that work is held by a clinician, a quarterly retreat, a journaling practice, or all of the above, the goal was never to need nothing. The goal was always to live better, more fully, and with greater understanding of oneself.

While some that stigma is cultural, some of it, honestly, is coming from the professionals in the field — from the way we market these therapies, the language we use in intake, the reaction your team might when a patient comes back.

For the clinicians providing this care, the staff supporting these practices, and the scientists communicating this data, setting that expectation clearly and compassionately is your responsibility. The return visit isn't a setback. It was always part of the plan.

If you'd like support building a team that can hold this type of patient-conversation, and many other important ones, we'd love to help.
Learn more about how we support new and emerging practices HERE, and contact us HERE.